ARK Genomic Revolution ETF Newsroom

Adaptive Biotechnologies Analyst Ratings

BenzingaDec 18 23:54 · Ratings

New Strategy? Cathie Wood's ARK Purchases Shares in Futu, Significantly Increased Its Stake in AI Healthcare Company Tempus AI and Sold Off Shopify

Cathie Wood's ARK ETF announced the daily Trade details for Tuesday, December 17, 2024.

Futu NewsDec 18 18:22

Natera Analyst Ratings

BenzingaDec 13 22:00 · Ratings

Annual review | The top ten explosive stocks in the US stock market for 2024 have been released! Applovin emerges as the dark horse of the year in AI, MSTR astonishes the market with a fivefold increase for the year, and Tesla makes a comeback in the last

As of the market close on December 11, the S&P 500 Index has risen by 27% year-to-date, surpassing 6,000 points; the Nasdaq Composite Index has accumulated a rise of over 33%, reaching a milestone of 0.02 million points, exceeding market expectations.

Futu NewsDec 12 21:40

Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites

BenzingaDec 12 21:06

Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company

BenzingaDec 12 10:30

Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning

Seeking AlphaDec 12 06:18

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

BenzingaDec 11 21:26 · Ratings

Recursion Pharmaceuticals Analyst Ratings

BenzingaDec 11 21:25 · Ratings

Top 3 Health Care Stocks That May Collapse This Quarter

BenzingaDec 11 19:55

10 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 11 01:35

What's Going On With Recursion Pharmaceuticals Stock?

BenzingaDec 10 22:55

Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target

BenzingaDec 10 20:39 · Ratings

CRISPR Therapeutics Analyst Ratings

BenzingaDec 10 20:38 · Ratings

Beam Therapeutics Analyst Ratings

BenzingaDec 10 01:37 · Ratings

Vertex Reports Positive Long-term Data for Casgevy

Seeking AlphaDec 10 01:17

CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...

BenzingaDec 10 01:03

Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains

BenzingaDec 10 00:10

Reported Sunday, Beam Therapeutics Showcases Proof-Of-Concept Non-Human Primate Data For ESCAPE, A Non-Genotoxic Antibody-Based Conditioning Strategy For Sickle Cell Disease, At ASH 2024

BenzingaDec 9 15:33

Executive Reshuffles: INTC, ZS, ETSY and SEDG

Seeking AlphaDec 8 04:54